Value Added Product Mix Shift
What: Pharma grade capacity: 12,300 MTPA
Commercial Syn Bags Ltd (Packaging - Polysacks) — fundamental analysis, earnings data, and key metrics. PE: 23.6. ROE: 12.3%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on Q3 FY26 (web) earnings • Updated Apr 19, 2026
What: Pharma grade capacity: 12,300 MTPA
What: Volume growth: 10%
Earnings deceleration risks from management commentary
Trigger: Vulnerability to volatile polypropylene (PP) and HDPE granule prices which are linked to crude oil.
Management view: Passing on costs to B2B customers where possible.
Monitor: commodity
Trigger: High freight costs on export sales, which account for over 70% of revenue.
Impact: PAT impact: ₹3.51 Cr (FY24 base)
Management view: Focusing on efficient logistics and regionalization.
Monitor: logistics
Headline numbers from the latest earnings call
Revenue
₹97.63 Cr
Revenue grew year-on-year driven by volume expansion but saw a marginal sequential dip.
PAT
₹6.00 Cr
Profitability showed significant annual improvement but faced sequential pressure likely due to rising raw material costs.
Other Highlights
• Net profit margin jumped 51.25% year-on-year to 6.15% in Q3 FY26.
• Standalone net profit for the quarter ended Dec 31, 2025, reached ₹6.25 crore.
• Board meeting held on Feb 5, 2026, approved the unaudited financial results.
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Export Revenue Contribution
70%
Why: The company maintains a strong global footprint across six continents.
Total Manufacturing Capacity
20,630 MTPA
Why: Ongoing capex of ₹83 crore to add 12,300 MTPA capacity for pharma grade products.
PP/HDPE Granule Exposure
High
Why: Granule prices are highly sensitive to crude oil fluctuations, impacting gross margins.
Debt to EBITDA Ratio
3.39x
Why: Reflects the debt-heavy nature of the current expansion phase.
Forward-looking targets from management for Q4 FY26
OPM Guidance
8%
Capex Plan
₹83 Cr
Rs 185 Cr (Q4 estimate)
Targeting high single-digit EBITDA margins
₹83.00 Cr
Capacity expansion of 12,300 MTPA for pharma grade bags
Positive volume trajectory expected
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 19, 2026.
Based on publicly available financial data. This is educational research, not investment advice.
Commercial Syn Bags Ltd's latest quarterly results (Dec 2025) show
Commercial Syn Bags Ltd's current PE ratio is 23.6x.
Commercial Syn Bags Ltd's price-to-book ratio is 4.0x.
Commercial Syn Bags Ltd's fundamental strength based on key financial ratios
Commercial Syn Bags Ltd has a debt-to-equity ratio of N/A.
Commercial Syn Bags Ltd's return ratios over recent years
Commercial Syn Bags Ltd's operating cash flow is positive (FY2025).
Commercial Syn Bags Ltd's current dividend yield is 0.24%.
Commercial Syn Bags Ltd's shareholding pattern (Mar 2026)
Commercial Syn Bags Ltd's promoter holding has increased recently.
Commercial Syn Bags Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Commercial Syn Bags Ltd has 2 key growth catalysts identified from recent earnings analysis
Commercial Syn Bags Ltd has 2 key risks worth monitoring
Commercial Syn Bags Ltd's management has provided the following forward guidance for Q4 FY26
Commercial Syn Bags Ltd's most important sub-sector-specific KPIs from the latest concall
Based on quantitative research signals, here is why Commercial Syn Bags Ltd may be worth studying
Commercial Syn Bags Ltd investment thesis summary:
Commercial Syn Bags Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.